中文 |
中文

Newsroom

Home / Newsroom / CAS in Media

Chinese Lipid-lowering Drug Candidate Proves Safe, Effective

Apr 22, 2022

 A new lipid-lowering drug candidate developed by Chinese researchers was proved safe and effective in its phase one clinical trial, the Chinese Academy of Sciences (CAS) said on Tuesday.
The drug, coded DC371739, was developed by researchers at the Shanghai Institute of Materia Medica under the CAS and was approved to undergo phase one clinical trial in 2020.
The candidate showed a promising lipid-lowering effect in vitro and in vivo, as well as good safety and tolerability both in healthy subjects and in patients with hyperlipidemia in the phase one trial, according to the research paper published in the journal Cell Metabolism.
Lipid-lowering drug statins are currently the main clinical treatment for hyperlipidemia, though they are not suitable for patients with statin intolerance.
Through combination with atorvastatin, a statin drug, the new candidate provides a potential therapeutic strategy for patients with statin intolerance due to its action mechanism that is distinct from other known lipid-lowering reagents, the paper said. (Xinhua)
Contact

E-mail:

Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

Related Articles
CAS-Developed Anti-SARS-CoV-2 Drug Candidate Enters Clinical Trial in the US
CAS-Developed Anti-SARS-CoV-2 Drug Candidate Enters Clinical Trial in the US
Mar 18, 2021

DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15. DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.

ICS: Lupus Drug Approved for Clinical Trials
ICS: Lupus Drug Approved for Clinical Trials
May 25, 2015

A group of local researchers has developed a new drug to treat Lupus, a disease in which the body's immune system mistakenly attacks healthy tissue. And the State Food and Drug Administration has approved the drug for clinical trials.

Contact Us

  • 86-10-68597521 (day)

    86-10-68597289 (night)

  • 52 Sanlihe Rd., Xicheng District,

    Beijing, China (100864)

Copyright © 2002 - Chinese Academy of Sciences